Crystalline forms of N-heteroaryl sulfonamides, compositions and methods thereof
A novel crystalline form of N-heteroaryl sulfonamide is developed with enhanced pharmacokinetic properties and stability, addressing the need for improved pharmaceutical compounds through specific characterization and preparation methods.
JP2026501757APending Publication Date: 2026-01-16PACYLEX PHARMA INC
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2025539957
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-01-06
- Filing Date
- 2023-12-28
- Publication Date
- 2026-01-16
AI Technical Summary
Technical Problem
There is a need for new crystalline forms of pharmaceutical compounds that exhibit better pharmacokinetic properties, bioavailability, and/or stability.
Method used
The development of a crystalline form of N-heteroaryl sulfonamide characterized by specific X-ray powder diffraction patterns, DSC thermograms, and Raman spectra, along with methods for preparing and recrystallizing this form using organic solvents and antisolvents.
Benefits of technology
The new crystalline form enhances pharmacokinetic properties and stability, providing improved bioavailability and suitability for pharmaceutical compositions.
✦ Generated by Eureka AI based on patent content.
Abstract
Crystalline forms of the N-heteroarylsulfonamide 2,6-dichloro-N-(3-isobutyl-1,5-dimethyl-1H-pyrazol-4-yl)-4-(2-(piperazin-1-yl)pyridin-4-yl)benzenesulfonamide and pharmaceutical compositions thereof; and methods of preparing the crystalline forms and methods of using the crystalline forms in the treatment of diseases.
Need to check novelty before this filing date? Find Prior Art